U.S. markets closed
  • S&P Futures

    3,839.50
    -6.50 (-0.17%)
     
  • Dow Futures

    31,024.00
    -58.00 (-0.19%)
     
  • Nasdaq Futures

    13,365.75
    -29.75 (-0.22%)
     
  • Russell 2000 Futures

    2,137.50
    -1.00 (-0.05%)
     
  • Crude Oil

    52.66
    -0.47 (-0.88%)
     
  • Gold

    1,865.30
    -0.60 (-0.03%)
     
  • Silver

    25.81
    -0.04 (-0.17%)
     
  • EUR/USD

    1.2173
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.1090
    +0.0190 (+1.74%)
     
  • Vix

    21.32
    -0.26 (-1.20%)
     
  • GBP/USD

    1.3724
    -0.0007 (-0.05%)
     
  • USD/JPY

    103.5610
    +0.0560 (+0.05%)
     
  • BTC-USD

    29,617.40
    +84.87 (+0.29%)
     
  • CMC Crypto 200

    583.73
    -96.18 (-14.15%)
     
  • FTSE 100

    6,715.42
    -24.97 (-0.37%)
     
  • Nikkei 225

    28,643.68
    -113.18 (-0.39%)
     

Precision BioSciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Precision Biosciences
·1 min read

DURHAM, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that its Chief Scientific Officer, Derek Jantz, Ph.D., will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference, November 30 – December 3, 2020.

This fireside chat has been pre-recorded and is now available for registered attendees via the Piper Sandler conference site until December 3. It is also available on Precision's website, www.PrecisionBiosciences.com in the Investors and Media section under Events and Presentations.

About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

Investor Contact:
Alex Kelly
Chief Corporate Affairs Officer
Alex.Kelly@precisionbiosciences.com